C-Rad AB
Company Announcement

GEMini™ Performance Test Results – Joint Testing With B2B Customer Agreed

Press release 2013-12-23

The C-RAD GEMini detector system has been especially designed for VMAT treatments in advanced radiation therapy. The detector will be used both as an imaging and dosimetry device.

A test with the clinical version of the GEMini detector verified the significant improvements in the image quality. After the positive result with a reduced field of view, clinical test with the full size detector will start in 2014.

Based on the presented performance of the GEMini detecter C-RAD agreed with a B2B customer to do joint testing. The test will take place in the next months. C-RAD will begin the preparation in January.

C-RAD Imaging has during 2013 focused the development on optimizing the image quality of the GEMini detector. As a result resolution and contrast have been taken to a new level. Clinical images were acquired in Salzburg, confirming these improvements. Some remaining scatter effects in the images have led to the development of a matrix filter plate to reduce internal scatter and therewith achieve higher image sharpness. For the innovative matrix filter a patent application has been submitted in the US.

Tim Thurn, CEO, C-RAD AB:

“The results are showing promising performance of the GEMini technology. With its two main applications in imaging and portal dosimetry C-RAD is developing a unique solution for a rapidly growing VMAT market. The next year will be exciting with the clinical tests as well as the joint testing together with our customer.”

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 29 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD Sentinel^TM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian  and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.

For more information on C-RAD, please visit www.c-rad.com.

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666931, E-mail investors@c-rad.com